Epidemiological Characteristics of Peripheral T-Cell Lymphoma: A Population-Based Study.

cancer registry epidemiology incidence mortality non-Hodgkin lymphoma peripheral T-cell lymphoma survival

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 27 01 2022
accepted: 20 06 2022
entrez: 1 8 2022
pubmed: 2 8 2022
medline: 2 8 2022
Statut: epublish

Résumé

The aim of this study is to explore the epidemiological characteristics of peripheral T-cell lymphoma in Beijing.  All data were extracted from the Beijing Cancer Registry database from January 1, 2007, to December 31, 2018. Segi's World Standard Population was used to estimate the age-standardized rate (ASR). Changes in trends were examined using joinpoint regression analysis. The observed survival was estimated by the Kaplan-Meier method. Relative survival was calculated using Ederer II and standardized using the Brenner method and International Cancer Survival Standard (ICSS) group 1 age structure. Stratified by gender, area, and histological type, incidence, mortality, and age of onset trends were observed in Beijing.  In Beijing, there were 801 new cases and 463 deaths of T-cell lymphoma from 2007 to 2018. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) was the most prevalent subtype (37.45%), followed by angioimmunoblastic T-cell lymphoma (AITL; 20.35%), NK/T-cell lymphoma (NK/TCL; 17.60%), and anaplastic large cell lymphoma (ALCL; 10.24%). The crude incidence and mortality rates were 0.52 and 0.30 per 100,000 person-years, respectively, whereas the age-standardized incidence and mortality rates (ASIR and ASMR) were 0.35 and 0.18 per 100,000 person-years, respectively. Both ASIR and ASMR were more prevalent in men (0.48 and 0.24 per 100,000) and urban area (0.38 and 0.19 per 100,000) than in women (0.22 and 0.11 per 100,000) and rural area (0.30 and 0.15 per 100,000). The average annual percentage change (AAPC) of ASIR and ASMR was 5.72% (95% confidence interval (CI): 1.79%-9.81%) and 4.35% (95% CI: -0.09%-8.99%), respectively. The age-specific incidence rate increased with age and peaked at the age groups of 10-14 and 80-84. The mean and median age of onset increased between 2007 and 2018. In addition, it decreased after the age of onset was age standardization (  T-cell lymphoma incidence was rising, but survival was dismal in Beijing, indicating the need for improved early diagnosis and standardized treatment.

Identifiants

pubmed: 35912210
doi: 10.3389/fonc.2022.863269
pmc: PMC9326059
doi:

Types de publication

Journal Article

Langues

eng

Pagination

863269

Informations de copyright

Copyright © 2022 Liu, Liu, Li, Yang, Song, Zhang, Cheng, Li, Li, Wang, Zhu and Ji.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Oncol. 2018 Dec 03;8:579
pubmed: 30560091
BMJ Open. 2021 Apr 30;11(4):e042762
pubmed: 33931407
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Br J Cancer. 2015 Apr 28;112(9):1575-84
pubmed: 25867256
Cancer Med. 2020 Jun;9(11):3765-3774
pubmed: 32281275
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Front Oncol. 2021 Nov 04;11:750323
pubmed: 34804937
J Clin Oncol. 2012 Sep 1;30(25):3093-9
pubmed: 22851556
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):668-676.e5
pubmed: 32605898
J Hematol Oncol. 2019 Mar 4;12(1):22
pubmed: 30832702
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Haematologica. 2018 Jul;103(7):1191-1197
pubmed: 29599200
J Hematol Oncol. 2019 Nov 19;12(1):115
pubmed: 31744509
Int J Cancer. 2015 Sep 1;137(5):1217-23
pubmed: 25694231
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Cancer Med. 2018 Nov;7(11):5843-5858
pubmed: 30311404
J Clin Oncol. 2016 Mar 20;34(9):963-71
pubmed: 26962200
CA Cancer J Clin. 2020 Jan;70(1):47-70
pubmed: 31815293
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jun 6;52(6):593-600
pubmed: 29886680
Cancers (Basel). 2021 Oct 18;13(20):
pubmed: 34680362
J Clin Oncol. 2013 Jun 1;31(16):1970-6
pubmed: 23610113
Front Med (Lausanne). 2021 Nov 05;8:732727
pubmed: 34805202
Cancer Res Treat. 2018 Jan;50(1):222-238
pubmed: 28361523

Auteurs

Shuo Liu (S)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Weiping Liu (W)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.

Huichao Li (H)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Lei Yang (L)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Yuqin Song (Y)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.

Xi Zhang (X)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Yangyang Cheng (Y)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Qingyu Li (Q)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Haoxin Li (H)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Ning Wang (N)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.

Jun Zhu (J)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.

Jiafu Ji (J)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing, China.

Classifications MeSH